Streetwise Reports' Article Archives — April 2021 back to current month (20)
Shares of CryoLife Inc. set a new 52-week high intraday price after the company reported that total revenues in Q1/21 increased by 7% YoY to $71.1 million.
Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was shown to nearly double median overall survival time in patients with locally advanced pancreatic cancer.
The clinical trial, in which Sorrento Therapeutics established safety, and the company's next steps for this potential treatment are summarized in a Dawson James Securities report.
Avivagen Inc. reported it received a 4.4 metric tonne purchase order for OxC-beta Livestock from UNAHCO representing its largest single order to date.
ADMA Biologics shares traded 9% higher after the company received FDA approval for increased intravenous immune globulin production scale, allowing the firm to increase manufacturing capacity from 400,000 to 600,000 liters and achieve peak revenues of greater than $300 million.
Aldeyra Therapeutics shares traded 33% higher after the firm reported that reproxalap significantly met all primary and secondary endpoints in its Phase 3 allergic conjunctivitis study.
Ocugen Inc. shares traded up as much as 47% before closing just 3.66% higher after the company announced a $100 million registered direct offering of common stock priced at a $10 per share, which represents a premium to the market price.
Healthcare Services Group Inc.'s shares traded 13% higher after the company reported Q1/21 financial results that included a 22% YoY increase in net income.
Is the Trend Turning for This Psychedelic Stock? (04/19/2021)
Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point.
Novamind runs clinics, research sites and therapeutic retreats and is positioning itself for expansion.
A Research Capital Corp. report discusses CloudMD Software & Services' acquisition of Oncidium, "one of Canada's leading health management companies."
Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia.
Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock.
Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer.
Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells.
Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities."
Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report.
Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million.
Shares of Nano-X Imaging Ltd. traded 17% higher after the company reported that the FDA has granted 510(k) approval for its single source ARC digital x-ray.
United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its TyvasoŽ Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease.
|"We expect PMN to commence formal Phase 1 testing later this year."|